GoPro Inc vs uniQure N.V. Ordinary Shares — how do they compare? GoPro Inc trades at $1.1 (market cap $238.34M), while uniQure N.V. Ordinary Shares trades at $21.51 (market cap $1.45B). The key difference: uniQure N.V. Ordinary Shares is far larger — about 6.1× GoPro Inc's market cap, and GoPro Inc is more actively traded (5,242,039 versus 3,323,243). Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| GPRO | QURE | |
|---|---|---|
Market Cap | $238.34M | $1.45B |
Volume | 5,242,039 | 3,323,243 |
Sector | Technology | Health |
52-Week High | $2.31 | $70.59 |
52-Week Low | $0.58 | $9.03 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | $297.12M | $707.46M |
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $1.18, down 0.84% on the day, following recent volatility driven by merger speculation and influencer investment. The stock shows bullish technical signals with oversold RSI conditions, while fundamentals reveal persistent challenges with negative net income margins (-28.52%) and declining revenue trends from $1.1B in 2022 to $652M in 2025. The company announced a $285 million merger with Starman Optical and received 11 industry awards for its MISSION 1 series, providing potential catalysts amid ongoing financial struggles.
Investment outlook remains highly speculative with significant execution risks. The merger offers potential upside but faces shareholder litigation over valuation concerns. Analyst consensus shows cautious sentiment with only 21% buy ratings, while cash flow deficits and competitive pressures from smartphone technology create substantial headwinds for sustainable recovery.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →